share_log

StockNews.com Initiates Coverage on LadRx (NASDAQ:CYTR)

Defense World ·  Jan 16, 2023 03:41

Equities research analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a research report issued to clients and investors on Monday. The brokerage set a "hold" rating on the stock.

LadRx Stock Performance

CYTR stock opened at $0.09 on Monday. The company has a 50 day moving average price of $0.10 and a 200 day moving average price of $0.12. LadRx has a fifty-two week low of $0.05 and a fifty-two week high of $0.86.

Get LadRx alerts:

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Further Reading

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • General Electric Stock, The Sum of All Parts Strategy is Paying Off
  • MarketBeat: Week in Review 01/09-01/13
  • JPMorgan Chase Falls As Banks Brace For Recession
  • Why is the Bed Bath & Beyond Stock Price up 261%?
  • Roku Stock Price is Trending, Here's Why

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment